.jetcityimage/iStock Content via Getty Images Morgan Stanley has decided on Eli Lilly (NYSE: LLY) as its leading biopharma pick for 2025 and also rated an additional nine labels in the space as overweight. The expenditure financial institution said in a details that it continues to believe “diabesity is readied to end up being.